Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

simvastatin

- PMLiVE

Novo Nordisk finally bags insulin degludec approval in US

Aims to get Tresiba and Ryzodeg back on course 

- PMLiVE

FDA rejects AZ’s diabetes combination

Wants to see more trial data on saxagliptin / dapagliflozin

Bristol-Myers Squibb (BMS) building

BMS gets OK for broader Opdivo use in lung cancer

US regulator'sdecision allows firm to edge in front of Merck & Co's Keytruda

Eli Lilly HQ

Lilly wins breakthrough designation for breast cancer drug

CDK 4 and 6 inhibitor Abemaciclib's development to be expedited by FDA

- PMLiVE

FDA fast-tracks Merck/Pfizer’s rare skin cancer drug avelumab

Comes a month after drug was given orphan status

Bristol-Myers Squibb (BMS) building

BMS bags US approval for Opdivo and Yervoy combo

Marks first approval for joint use of two immuno-oncology drugs

- PMLiVE

Merck gets lung cancer OK for Keytruda in US

Highlights increased understanding of molecular processes in cancer

MSD launches preventative healthcare accelerator

Joins forces with Wayra Open Future for VelocityHealth fund

Sanofi reception

Sanofi’s lixisenatide is back under FDA review

Brings GLP-1 agonist closer to US market

- PMLiVE

Merck gets first OK for once-weekly DPP-4 inhibitor

Marizev approved in Japan

- PMLiVE

FDA clears Taiho’s oral colorectal cancer drug

Regulatory nod for Lonsurf gives patients additional treatment options

- PMLiVE

Amgen granted priority review for extended use of Kyprolis

Trial data shows myeloma drug's improvement over Velcade

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links